NASHVILLE, Tenn.–(BUSINESS WIRE)–Nov 12, 2024–
Sarah Cannon Research Institute (SCRI), one of the world’s leading oncology research organizations conducting community-based clinical trials, is pleased to announce that Krish Patel, MD, has been appointed Director, Lymphoma Research, for SCRI. The addition of the strategic appointment will bolster SCRI’s capacity to enhance its comprehensive lymphoma clinical trial portfolio and advance clinical research across its extensive network of nearly 250 locations. In addition to his leadership role at SCRI, Dr. Patel will serve as a medical oncologist at SCRI Oncology Partners in Nashville, Tenn starting in mid-November.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241112162975/en/
Krish Patel, MD (Photo: Business Wire)
“We are pleased to welcome Dr. Patel as we continue our mission to provide cutting-edge clinical research in the community,” said David Spigel, Chief Scientific Officer of SCRI. “Dr. Patel’s role will be pivotal in providing scientific leadership and oversight for our robust menu of lymphoma clinical trials, addressing a critical need with nearly 90,000 new U.S. cases of lymphoma estimated in 2023.”